Neuroprotective compounds for treating optic neuropathies and screening methods for identifying neuroprotective compounds.

Neuroprotective compounds for treating optic neuropathies and screening methods for identifying neuroprotective compounds.

The invention concerns a compound of Formula (I) or a salt thereof, wherein R.sub.1 is H, (C.sub.1-C.sub.3)alkyl or CF.sub.3; R.sub.2 is H, (C.sub.1-C.sub.3)alkyl or CF.sub.3; A is CH.sub.2COOH, XCH.sub.2COOCH.sub.2CH.sub.3, XCH.sub.2COOH, XCH.sub.2CH.sub.2NH.sub.2, where X is nitrogen or oxygen atom; Ar is an aromatic fragment selected from the group consisting of (Ar1), (Ar2) and (Ar3); where R.sub.3 is H, —CH.sub.3, —CH.sub.2CH.sub.3 or CH.sub.3CO—, R.sub.4 is H or —CH.sub.3, R5 is H or —CH.sub.3, and R.sub.6 is H or —CH.sub.3. The compounds of Formula (I) can be used in the treatment of diseases modulated by thyroid hormone receptor-beta (TRb or TRβ).

The present invention relates to N-(7-fluoro-1,1,3-trimethyl-1H-inden-4yl) amides and a process for preparing same. The novel amides are useful in a process for converting the unwanted S enantiomer form of a 4-aminoindane derivative to its useful raceme.

The present invention relates to N-(7-fluoro-1,1,3-trimethyl-1H-inden-4yl) amides and a process for preparing same. The novel amides are useful in a process for converting the unwanted S enantiomer form of a 4-aminoindane derivative to its useful raceme.

Useful processes of preparation and intermediates useful for the preparation of Compound 1, a selective estrogen receptor alpha (ERα) modulator/degrader (SERM/SERD), having utility for the treatment of ER+ cancers including breast cancer are described.

Useful processes of preparation and intermediates useful for the preparation of Compound 1, a selective estrogen receptor alpha (ERα) modulator/degrader (SERM/SERD), having utility for the treatment of ER+ cancers including breast cancer are described.

Useful processes of preparation and intermediates useful for the preparation of Compound 1, a selective estrogen receptor alpha (ERα) modulator/degrader (SERM/SERD), having utility for the treatment of ER+ cancers including breast cancer are described.

The present invention provides a compound, and method of inhibiting the activity of a Fatty Acid Binding Protein (FABP) comprising contacting the FABP with a compound, said compound having the structure: Formula (I) ##STR00001##

The present invention provides a compound, and method of inhibiting the activity of a Fatty Acid Binding Protein (FABP) comprising contacting the FABP with a compound, said compound having the structure: Formula (I) ##STR00001##